*Five Years Citation in Google scholar (2016 - 2020) is. 1451*   *    IJPR IS INDEXED IN ELSEVIER EMBASE & EBSCO *         Journal is Currently Not Indexed in Scopus as on february 2021 list Updated by scopus

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence
Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
A Systematic Review on Safety and Efficacy of Hydroxyurea in Sickle Cell Anemia in Pediatric Population

Author: RAJESH HADIA, SUNIL KARDANI, DHAVAL JOSHI
Abstract: Sickle cell disease involves a large group of congenital hemolytic anemias, but all are characterized by the presence of sickle hemoglobin (HbS). The most commonly observed SCD is of two types. One is Sickle cell Anemia which is also known as homozygous HbSS, and the other one is beta-thalassemia which is also known as HbSC. Clinical manifestations of SCA include hemolytic anemia, susceptibility to infection which is secondary to splenic dysfunction, vaso occlusive events which are painful and acute, Chronic organ damage or malfunction, stroke and early mortality is seen in pediatric patients. Though the long term risks and benefits of Hydroxyurea is not known, the panel of National Institutes of Health Consensus Conference suggested that in SCA the risks associated with usage of Hydroxyurea are acceptable when compared to the dangers of untreated sickle cell disease. In sickle cell anemia RBCs will be in sickle cell shape once-daily dosing of Hydroxyurea in SCA patients leads to temporary arrest of hemopoiesis. The physiology and erythropoiesis kinetics leads to recruitment of erythroid progenitors which maintain proper HbF levels. There is no clinical evidence that suggests that Hydroxyurea may cause teratogenicity, but further investigations are mandatory in testing hydroxyurea in pregnant women. There are very few data regarding an increase in the risk of miscarriage and maternal death though SCA is risky in pregnancy. Thus, in the present study, we have aimed to study the safety and efficacy profile of Hydroxyurea in Patients with Sickle Cell Anemia, especially in the Pediatric population.
Keyword: Sickle cell anemia, Pediatric population, Hydroxyurea, Red Blood cells.
DOI: https://doi.org/10.31838/ijpr/2019.11.02.223
Download: Request For Article
 




ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free